CD8A and juvenile idiopathic arthritis: Given the safety of long-term use and anti-inflammatory effects on CD4+ and CD8+ T-cells, we propose NAM as a promising therapeutic approach, specifically as an add-on medication or as a maintenance therapy in relapsing-remitting diseases like RA or JIA.